nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—hematologic cancer—muscle cancer	0.48	1	CtDrD
Dasatinib—KIT—muscle cancer	0.223	1	CbGaD
Dasatinib—CYP1A1—Dacarbazine—muscle cancer	0.017	0.141	CbGbCtD
Dasatinib—ABCG2—Dactinomycin—muscle cancer	0.0159	0.132	CbGbCtD
Dasatinib—CYP1B1—Doxorubicin—muscle cancer	0.0129	0.107	CbGbCtD
Dasatinib—ABCG2—Vincristine—muscle cancer	0.00982	0.0813	CbGbCtD
Dasatinib—ABCG2—Etoposide—muscle cancer	0.009	0.0745	CbGbCtD
Dasatinib—CYP1A2—Dacarbazine—muscle cancer	0.00758	0.0628	CbGbCtD
Dasatinib—ABCG2—Doxorubicin—muscle cancer	0.00614	0.0508	CbGbCtD
Dasatinib—ABCG2—Methotrexate—muscle cancer	0.00594	0.0492	CbGbCtD
Dasatinib—ABCB1—Dactinomycin—muscle cancer	0.00575	0.0476	CbGbCtD
Dasatinib—CYP3A5—Vincristine—muscle cancer	0.00544	0.0451	CbGbCtD
Dasatinib—CYP3A5—Etoposide—muscle cancer	0.00498	0.0413	CbGbCtD
Dasatinib—CYP1A2—Etoposide—muscle cancer	0.00371	0.0307	CbGbCtD
Dasatinib—ABCB1—Vincristine—muscle cancer	0.00354	0.0293	CbGbCtD
Dasatinib—ABCB1—Etoposide—muscle cancer	0.00324	0.0269	CbGbCtD
Dasatinib—ABCB1—Doxorubicin—muscle cancer	0.00221	0.0183	CbGbCtD
Dasatinib—ABCB1—Methotrexate—muscle cancer	0.00214	0.0178	CbGbCtD
Dasatinib—CYP3A4—Vincristine—muscle cancer	0.00212	0.0176	CbGbCtD
Dasatinib—CYP3A4—Etoposide—muscle cancer	0.00194	0.0161	CbGbCtD
Dasatinib—CYP3A4—Doxorubicin—muscle cancer	0.00133	0.011	CbGbCtD
Dasatinib—ERBB3—Podofilox—Etoposide—muscle cancer	0.000462	0.285	CbGdCrCtD
Dasatinib—TXK—bone marrow—muscle cancer	0.000331	0.00613	CbGeAlD
Dasatinib—SIK3—cardiac atrium—muscle cancer	0.00033	0.00611	CbGeAlD
Dasatinib—EPHA4—embryo—muscle cancer	0.000329	0.00609	CbGeAlD
Dasatinib—ERBB3—embryo—muscle cancer	0.000325	0.00603	CbGeAlD
Dasatinib—SIK2—head—muscle cancer	0.000325	0.00603	CbGeAlD
Dasatinib—ERBB3—Vinblastine—Vincristine—muscle cancer	0.000318	0.196	CbGdCrCtD
Dasatinib—TXK—vagina—muscle cancer	0.000317	0.00587	CbGeAlD
Dasatinib—PKMYT1—head—muscle cancer	0.000317	0.00587	CbGeAlD
Dasatinib—PTK6—vagina—muscle cancer	0.000314	0.00581	CbGeAlD
Dasatinib—STAT5B—bone marrow—muscle cancer	0.00031	0.00574	CbGeAlD
Dasatinib—FRK—testis—muscle cancer	0.000306	0.00567	CbGeAlD
Dasatinib—PKMYT1—testis—muscle cancer	0.000306	0.00567	CbGeAlD
Dasatinib—MAPK14—embryo—muscle cancer	0.000303	0.00562	CbGeAlD
Dasatinib—TESK1—renal system—muscle cancer	0.000303	0.00561	CbGeAlD
Dasatinib—EPHB2—head—muscle cancer	0.000302	0.0056	CbGeAlD
Dasatinib—FGR—embryo—muscle cancer	0.000302	0.00559	CbGeAlD
Dasatinib—SRMS—head—muscle cancer	0.000296	0.00548	CbGeAlD
Dasatinib—TXK—head—muscle cancer	0.000293	0.00543	CbGeAlD
Dasatinib—EPHA8—head—muscle cancer	0.00029	0.00537	CbGeAlD
Dasatinib—CSK—smooth muscle tissue—muscle cancer	0.000288	0.00534	CbGeAlD
Dasatinib—SIK3—tendon—muscle cancer	0.000287	0.00533	CbGeAlD
Dasatinib—JAK2—embryo—muscle cancer	0.000285	0.00529	CbGeAlD
Dasatinib—TXK—testis—muscle cancer	0.000283	0.00524	CbGeAlD
Dasatinib—FYN—embryo—muscle cancer	0.000281	0.00521	CbGeAlD
Dasatinib—EPHA8—testis—muscle cancer	0.00028	0.00519	CbGeAlD
Dasatinib—CSK—renal system—muscle cancer	0.000277	0.00514	CbGeAlD
Dasatinib—STAT5B—head—muscle cancer	0.000274	0.00508	CbGeAlD
Dasatinib—TESK1—cardiac atrium—muscle cancer	0.000271	0.00502	CbGeAlD
Dasatinib—ZAK—tendon—muscle cancer	0.000267	0.00495	CbGeAlD
Dasatinib—STAT5B—testis—muscle cancer	0.000265	0.00491	CbGeAlD
Dasatinib—BTK—tendon—muscle cancer	0.000255	0.00472	CbGeAlD
Dasatinib—EPHA3—head—muscle cancer	0.000253	0.00469	CbGeAlD
Dasatinib—SIK1—renal system—muscle cancer	0.000251	0.00466	CbGeAlD
Dasatinib—STK35—cardiac atrium—muscle cancer	0.00025	0.00463	CbGeAlD
Dasatinib—PDGFRA—embryo—muscle cancer	0.000249	0.00462	CbGeAlD
Dasatinib—CSK—cardiac atrium—muscle cancer	0.000248	0.0046	CbGeAlD
Dasatinib—ZAK—vagina—muscle cancer	0.000248	0.0046	CbGeAlD
Dasatinib—BTK—bone marrow—muscle cancer	0.000247	0.00458	CbGeAlD
Dasatinib—SIK3—head—muscle cancer	0.000246	0.00457	CbGeAlD
Dasatinib—ERBB3—renal system—muscle cancer	0.000246	0.00456	CbGeAlD
Dasatinib—EPHA3—testis—muscle cancer	0.000245	0.00453	CbGeAlD
Dasatinib—SRC—embryo—muscle cancer	0.000244	0.00453	CbGeAlD
Dasatinib—EPHA5—vagina—muscle cancer	0.000243	0.0045	CbGeAlD
Dasatinib—MAPK14—smooth muscle tissue—muscle cancer	0.000238	0.00442	CbGeAlD
Dasatinib—SIK3—testis—muscle cancer	0.000238	0.00441	CbGeAlD
Dasatinib—BTK—vagina—muscle cancer	0.000236	0.00438	CbGeAlD
Dasatinib—TESK1—tendon—muscle cancer	0.000236	0.00438	CbGeAlD
Dasatinib—STK36—tendon—muscle cancer	0.000232	0.00431	CbGeAlD
Dasatinib—RIPK2—cardiac atrium—muscle cancer	0.00023	0.00427	CbGeAlD
Dasatinib—MAPK14—renal system—muscle cancer	0.000229	0.00425	CbGeAlD
Dasatinib—ZAK—head—muscle cancer	0.000229	0.00425	CbGeAlD
Dasatinib—EPHB4—smooth muscle tissue—muscle cancer	0.000226	0.00419	CbGeAlD
Dasatinib—SIK1—cardiac atrium—muscle cancer	0.000225	0.00417	CbGeAlD
Dasatinib—JAK2—smooth muscle tissue—muscle cancer	0.000224	0.00416	CbGeAlD
Dasatinib—EPHA5—head—muscle cancer	0.000224	0.00415	CbGeAlD
Dasatinib—LYN—head—muscle cancer	0.000223	0.00413	CbGeAlD
Dasatinib—EPHA4—cardiac atrium—muscle cancer	0.000223	0.00413	CbGeAlD
Dasatinib—ZAK—testis—muscle cancer	0.000221	0.0041	CbGeAlD
Dasatinib—FYN—smooth muscle tissue—muscle cancer	0.000221	0.0041	CbGeAlD
Dasatinib—BMPR1B—head—muscle cancer	0.00022	0.00407	CbGeAlD
Dasatinib—MAP3K19—head—muscle cancer	0.00022	0.00407	CbGeAlD
Dasatinib—CSF1R—embryo—muscle cancer	0.000219	0.00406	CbGeAlD
Dasatinib—TESK1—vagina—muscle cancer	0.000219	0.00406	CbGeAlD
Dasatinib—STK35—tendon—muscle cancer	0.000218	0.00404	CbGeAlD
Dasatinib—EPHB4—renal system—muscle cancer	0.000217	0.00403	CbGeAlD
Dasatinib—CSK—tendon—muscle cancer	0.000216	0.00401	CbGeAlD
Dasatinib—MAP4K5—smooth muscle tissue—muscle cancer	0.000216	0.00401	CbGeAlD
Dasatinib—JAK2—renal system—muscle cancer	0.000216	0.004	CbGeAlD
Dasatinib—EPHB3—vagina—muscle cancer	0.000216	0.004	CbGeAlD
Dasatinib—STK36—vagina—muscle cancer	0.000216	0.004	CbGeAlD
Dasatinib—TNK2—head—muscle cancer	0.000215	0.00399	CbGeAlD
Dasatinib—HCK—tendon—muscle cancer	0.000214	0.00396	CbGeAlD
Dasatinib—FYN—renal system—muscle cancer	0.000213	0.00395	CbGeAlD
Dasatinib—ABL2—tendon—muscle cancer	0.000212	0.00393	CbGeAlD
Dasatinib—MAP3K19—testis—muscle cancer	0.000212	0.00393	CbGeAlD
Dasatinib—BMPR1B—testis—muscle cancer	0.000212	0.00393	CbGeAlD
Dasatinib—BTK—testis—muscle cancer	0.000211	0.00391	CbGeAlD
Dasatinib—CSK—bone marrow—muscle cancer	0.00021	0.00388	CbGeAlD
Dasatinib—LIMK2—vagina—muscle cancer	0.000208	0.00387	CbGeAlD
Dasatinib—TNK2—testis—muscle cancer	0.000208	0.00386	CbGeAlD
Dasatinib—HCK—bone marrow—muscle cancer	0.000207	0.00384	CbGeAlD
Dasatinib—CSK—Daunorubicin—Doxorubicin—muscle cancer	0.000206	0.127	CbGdCrCtD
Dasatinib—CSK—Epirubicin—Doxorubicin—muscle cancer	0.000206	0.127	CbGdCrCtD
Dasatinib—TESK1—head—muscle cancer	0.000202	0.00375	CbGeAlD
Dasatinib—STK35—vagina—muscle cancer	0.000202	0.00375	CbGeAlD
Dasatinib—RIPK2—tendon—muscle cancer	0.000201	0.00372	CbGeAlD
Dasatinib—CSK—vagina—muscle cancer	0.000201	0.00372	CbGeAlD
Dasatinib—YES1—smooth muscle tissue—muscle cancer	0.0002	0.0037	CbGeAlD
Dasatinib—EPHB3—head—muscle cancer	0.000199	0.00369	CbGeAlD
Dasatinib—STK36—head—muscle cancer	0.000199	0.00369	CbGeAlD
Dasatinib—KIT—embryo—muscle cancer	0.000199	0.00369	CbGeAlD
Dasatinib—HCK—vagina—muscle cancer	0.000198	0.00367	CbGeAlD
Dasatinib—ABL2—vagina—muscle cancer	0.000197	0.00365	CbGeAlD
Dasatinib—SIK1—tendon—muscle cancer	0.000196	0.00364	CbGeAlD
Dasatinib—PDGFRA—smooth muscle tissue—muscle cancer	0.000196	0.00363	CbGeAlD
Dasatinib—TESK1—testis—muscle cancer	0.000196	0.00363	CbGeAlD
Dasatinib—EPHB4—cardiac atrium—muscle cancer	0.000195	0.00361	CbGeAlD
Dasatinib—RIPK2—bone marrow—muscle cancer	0.000195	0.00361	CbGeAlD
Dasatinib—PDGFRB—embryo—muscle cancer	0.000194	0.0036	CbGeAlD
Dasatinib—EPHA4—tendon—muscle cancer	0.000194	0.0036	CbGeAlD
Dasatinib—JAK2—cardiac atrium—muscle cancer	0.000193	0.00358	CbGeAlD
Dasatinib—LIMK2—head—muscle cancer	0.000193	0.00357	CbGeAlD
Dasatinib—EPHB3—testis—muscle cancer	0.000192	0.00357	CbGeAlD
Dasatinib—STK36—testis—muscle cancer	0.000192	0.00357	CbGeAlD
Dasatinib—YES1—renal system—muscle cancer	0.000192	0.00356	CbGeAlD
Dasatinib—SRC—smooth muscle tissue—muscle cancer	0.000192	0.00356	CbGeAlD
Dasatinib—EPHA2—cardiac atrium—muscle cancer	0.000191	0.00354	CbGeAlD
Dasatinib—FYN—cardiac atrium—muscle cancer	0.000191	0.00353	CbGeAlD
Dasatinib—SIK1—bone marrow—muscle cancer	0.00019	0.00352	CbGeAlD
Dasatinib—PDGFRA—renal system—muscle cancer	0.000188	0.00349	CbGeAlD
Dasatinib—STK35—head—muscle cancer	0.000187	0.00346	CbGeAlD
Dasatinib—RIPK2—vagina—muscle cancer	0.000186	0.00345	CbGeAlD
Dasatinib—MAP4K5—cardiac atrium—muscle cancer	0.000186	0.00345	CbGeAlD
Dasatinib—MAP3K3—cardiac atrium—muscle cancer	0.000186	0.00345	CbGeAlD
Dasatinib—LIMK2—testis—muscle cancer	0.000186	0.00345	CbGeAlD
Dasatinib—CSK—head—muscle cancer	0.000185	0.00344	CbGeAlD
Dasatinib—SRC—renal system—muscle cancer	0.000185	0.00343	CbGeAlD
Dasatinib—MAP3K2—bone marrow—muscle cancer	0.000184	0.00342	CbGeAlD
Dasatinib—HCK—head—muscle cancer	0.000183	0.00339	CbGeAlD
Dasatinib—STK35—testis—muscle cancer	0.00018	0.00334	CbGeAlD
Dasatinib—EPHA4—vagina—muscle cancer	0.00018	0.00334	CbGeAlD
Dasatinib—CSK—testis—muscle cancer	0.000179	0.00332	CbGeAlD
Dasatinib—MAPK14—tendon—muscle cancer	0.000179	0.00332	CbGeAlD
Dasatinib—FGR—tendon—muscle cancer	0.000178	0.0033	CbGeAlD
Dasatinib—EPHB6—cardiac atrium—muscle cancer	0.000178	0.0033	CbGeAlD
Dasatinib—HCK—testis—muscle cancer	0.000177	0.00328	CbGeAlD
Dasatinib—ABL2—testis—muscle cancer	0.000176	0.00326	CbGeAlD
Dasatinib—MAPK14—bone marrow—muscle cancer	0.000173	0.00321	CbGeAlD
Dasatinib—ABL1—embryo—muscle cancer	0.000173	0.00321	CbGeAlD
Dasatinib—FGR—bone marrow—muscle cancer	0.000173	0.0032	CbGeAlD
Dasatinib—LCK—bone marrow—muscle cancer	0.000173	0.0032	CbGeAlD
Dasatinib—CSF1R—smooth muscle tissue—muscle cancer	0.000172	0.0032	CbGeAlD
Dasatinib—RIPK2—head—muscle cancer	0.000172	0.00319	CbGeAlD
Dasatinib—YES1—cardiac atrium—muscle cancer	0.000172	0.00319	CbGeAlD
Dasatinib—EPHB4—tendon—muscle cancer	0.00017	0.00315	CbGeAlD
Dasatinib—JAK2—tendon—muscle cancer	0.000168	0.00312	CbGeAlD
Dasatinib—SIK1—head—muscle cancer	0.000168	0.00312	CbGeAlD
Dasatinib—EPHA2—tendon—muscle cancer	0.000166	0.00309	CbGeAlD
Dasatinib—EPHA4—head—muscle cancer	0.000166	0.00308	CbGeAlD
Dasatinib—RIPK2—testis—muscle cancer	0.000166	0.00308	CbGeAlD
Dasatinib—FYN—tendon—muscle cancer	0.000166	0.00308	CbGeAlD
Dasatinib—MAPK14—vagina—muscle cancer	0.000166	0.00308	CbGeAlD
Dasatinib—SRC—cardiac atrium—muscle cancer	0.000166	0.00307	CbGeAlD
Dasatinib—FGR—vagina—muscle cancer	0.000165	0.00307	CbGeAlD
Dasatinib—LCK—vagina—muscle cancer	0.000165	0.00307	CbGeAlD
Dasatinib—ERBB3—head—muscle cancer	0.000165	0.00305	CbGeAlD
Dasatinib—EPHB4—bone marrow—muscle cancer	0.000164	0.00305	CbGeAlD
Dasatinib—JAK2—bone marrow—muscle cancer	0.000163	0.00303	CbGeAlD
Dasatinib—MAP3K2—head—muscle cancer	0.000163	0.00302	CbGeAlD
Dasatinib—MAP4K5—tendon—muscle cancer	0.000162	0.00301	CbGeAlD
Dasatinib—MAP3K3—tendon—muscle cancer	0.000162	0.00301	CbGeAlD
Dasatinib—SIK1—testis—muscle cancer	0.000162	0.00301	CbGeAlD
Dasatinib—FYN—bone marrow—muscle cancer	0.000161	0.00298	CbGeAlD
Dasatinib—EPHA4—testis—muscle cancer	0.000161	0.00298	CbGeAlD
Dasatinib—FMO3—vagina—muscle cancer	0.00016	0.00296	CbGeAlD
Dasatinib—ERBB3—testis—muscle cancer	0.000159	0.00295	CbGeAlD
Dasatinib—MAP3K2—testis—muscle cancer	0.000158	0.00292	CbGeAlD
Dasatinib—EPHB4—vagina—muscle cancer	0.000157	0.00292	CbGeAlD
Dasatinib—MAP4K5—bone marrow—muscle cancer	0.000157	0.00292	CbGeAlD
Dasatinib—MAP3K3—bone marrow—muscle cancer	0.000157	0.00292	CbGeAlD
Dasatinib—KIT—smooth muscle tissue—muscle cancer	0.000157	0.0029	CbGeAlD
Dasatinib—JAK2—vagina—muscle cancer	0.000156	0.0029	CbGeAlD
Dasatinib—EPHB6—tendon—muscle cancer	0.000155	0.00288	CbGeAlD
Dasatinib—EPHA2—vagina—muscle cancer	0.000154	0.00286	CbGeAlD
Dasatinib—FYN—vagina—muscle cancer	0.000154	0.00286	CbGeAlD
Dasatinib—MAPK14—head—muscle cancer	0.000153	0.00284	CbGeAlD
Dasatinib—PDGFRB—smooth muscle tissue—muscle cancer	0.000153	0.00283	CbGeAlD
Dasatinib—FGR—head—muscle cancer	0.000153	0.00283	CbGeAlD
Dasatinib—MAP2K5—cardiac atrium—muscle cancer	0.000152	0.00282	CbGeAlD
Dasatinib—MAP4K5—vagina—muscle cancer	0.000151	0.00279	CbGeAlD
Dasatinib—MAP3K3—vagina—muscle cancer	0.000151	0.00279	CbGeAlD
Dasatinib—KIT—renal system—muscle cancer	0.000151	0.00279	CbGeAlD
Dasatinib—YES1—tendon—muscle cancer	0.00015	0.00278	CbGeAlD
Dasatinib—CSF1R—cardiac atrium—muscle cancer	0.000149	0.00275	CbGeAlD
Dasatinib—MAPK14—testis—muscle cancer	0.000148	0.00275	CbGeAlD
Dasatinib—FGR—testis—muscle cancer	0.000148	0.00274	CbGeAlD
Dasatinib—LCK—testis—muscle cancer	0.000148	0.00274	CbGeAlD
Dasatinib—FMO3—head—muscle cancer	0.000148	0.00274	CbGeAlD
Dasatinib—PDGFRB—renal system—muscle cancer	0.000147	0.00273	CbGeAlD
Dasatinib—PDGFRA—tendon—muscle cancer	0.000147	0.00273	CbGeAlD
Dasatinib—YES1—bone marrow—muscle cancer	0.000145	0.00269	CbGeAlD
Dasatinib—JAK2—head—muscle cancer	0.000144	0.00268	CbGeAlD
Dasatinib—EPHB6—vagina—muscle cancer	0.000144	0.00267	CbGeAlD
Dasatinib—ABL1—Idarubicin—Doxorubicin—muscle cancer	0.000144	0.0885	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Doxorubicin—muscle cancer	0.000144	0.0885	CbGdCrCtD
Dasatinib—ABL1—Epirubicin—Doxorubicin—muscle cancer	0.000144	0.0885	CbGdCrCtD
Dasatinib—EPHA2—head—muscle cancer	0.000143	0.00264	CbGeAlD
Dasatinib—FMO3—testis—muscle cancer	0.000143	0.00264	CbGeAlD
Dasatinib—FYN—head—muscle cancer	0.000142	0.00264	CbGeAlD
Dasatinib—EPHB4—testis—muscle cancer	0.00014	0.0026	CbGeAlD
Dasatinib—JAK2—testis—muscle cancer	0.000139	0.00259	CbGeAlD
Dasatinib—MAP4K5—head—muscle cancer	0.000139	0.00258	CbGeAlD
Dasatinib—MAP3K3—head—muscle cancer	0.000139	0.00258	CbGeAlD
Dasatinib—YES1—vagina—muscle cancer	0.000139	0.00258	CbGeAlD
Dasatinib—EPHA2—testis—muscle cancer	0.000138	0.00255	CbGeAlD
Dasatinib—FYN—testis—muscle cancer	0.000138	0.00255	CbGeAlD
Dasatinib—PDGFRA—vagina—muscle cancer	0.000137	0.00253	CbGeAlD
Dasatinib—ABL1—smooth muscle tissue—muscle cancer	0.000136	0.00253	CbGeAlD
Dasatinib—MAP3K3—testis—muscle cancer	0.000134	0.00249	CbGeAlD
Dasatinib—MAP4K5—testis—muscle cancer	0.000134	0.00249	CbGeAlD
Dasatinib—EPHB6—head—muscle cancer	0.000133	0.00247	CbGeAlD
Dasatinib—MAP2K5—tendon—muscle cancer	0.000133	0.00246	CbGeAlD
Dasatinib—PDGFRB—cardiac atrium—muscle cancer	0.000132	0.00244	CbGeAlD
Dasatinib—ABL1—renal system—muscle cancer	0.000131	0.00243	CbGeAlD
Dasatinib—CSF1R—tendon—muscle cancer	0.00013	0.0024	CbGeAlD
Dasatinib—YES1—head—muscle cancer	0.000129	0.00238	CbGeAlD
Dasatinib—EPHB6—testis—muscle cancer	0.000128	0.00238	CbGeAlD
Dasatinib—PDGFRA—head—muscle cancer	0.000126	0.00234	CbGeAlD
Dasatinib—CSF1R—bone marrow—muscle cancer	0.000125	0.00233	CbGeAlD
Dasatinib—YES1—testis—muscle cancer	0.000124	0.0023	CbGeAlD
Dasatinib—SRC—head—muscle cancer	0.000124	0.00229	CbGeAlD
Dasatinib—MAP2K5—vagina—muscle cancer	0.000123	0.00228	CbGeAlD
Dasatinib—PDGFRA—testis—muscle cancer	0.000122	0.00226	CbGeAlD
Dasatinib—CSF1R—vagina—muscle cancer	0.00012	0.00223	CbGeAlD
Dasatinib—SRC—testis—muscle cancer	0.000119	0.00221	CbGeAlD
Dasatinib—ABL1—cardiac atrium—muscle cancer	0.000117	0.00218	CbGeAlD
Dasatinib—CYP1B1—smooth muscle tissue—muscle cancer	0.000115	0.00214	CbGeAlD
Dasatinib—PDGFRB—tendon—muscle cancer	0.000115	0.00213	CbGeAlD
Dasatinib—KIT—bone marrow—muscle cancer	0.000114	0.00211	CbGeAlD
Dasatinib—MAP2K5—head—muscle cancer	0.000114	0.00211	CbGeAlD
Dasatinib—PDGFRB—bone marrow—muscle cancer	0.000111	0.00206	CbGeAlD
Dasatinib—CYP1B1—renal system—muscle cancer	0.000111	0.00206	CbGeAlD
Dasatinib—CSF1R—head—muscle cancer	0.000111	0.00206	CbGeAlD
Dasatinib—MAP2K5—testis—muscle cancer	0.00011	0.00204	CbGeAlD
Dasatinib—KIT—vagina—muscle cancer	0.000109	0.00202	CbGeAlD
Dasatinib—CSF1R—testis—muscle cancer	0.000107	0.00199	CbGeAlD
Dasatinib—PDGFRB—vagina—muscle cancer	0.000107	0.00198	CbGeAlD
Dasatinib—ABL1—tendon—muscle cancer	0.000102	0.0019	CbGeAlD
Dasatinib—KIT—head—muscle cancer	0.000101	0.00187	CbGeAlD
Dasatinib—ABL1—bone marrow—muscle cancer	9.92e-05	0.00184	CbGeAlD
Dasatinib—PDGFRB—head—muscle cancer	9.85e-05	0.00183	CbGeAlD
Dasatinib—KIT—testis—muscle cancer	9.74e-05	0.00181	CbGeAlD
Dasatinib—PDGFRB—testis—muscle cancer	9.51e-05	0.00176	CbGeAlD
Dasatinib—ABL1—vagina—muscle cancer	9.5e-05	0.00176	CbGeAlD
Dasatinib—ABL1—head—muscle cancer	8.78e-05	0.00163	CbGeAlD
Dasatinib—CYP1B1—tendon—muscle cancer	8.67e-05	0.00161	CbGeAlD
Dasatinib—ABL1—testis—muscle cancer	8.48e-05	0.00157	CbGeAlD
Dasatinib—CYP1A2—renal system—muscle cancer	7.96e-05	0.00148	CbGeAlD
Dasatinib—CYP1A1—renal system—muscle cancer	7.85e-05	0.00146	CbGeAlD
Dasatinib—CYP3A5—renal system—muscle cancer	7.68e-05	0.00142	CbGeAlD
Dasatinib—CYP1B1—head—muscle cancer	7.43e-05	0.00138	CbGeAlD
Dasatinib—CYP1B1—testis—muscle cancer	7.18e-05	0.00133	CbGeAlD
Dasatinib—Cardiac failure—Doxorubicin—muscle cancer	7.08e-05	0.00142	CcSEcCtD
Dasatinib—Loss of consciousness—Etoposide—muscle cancer	7.05e-05	0.00142	CcSEcCtD
Dasatinib—Cerebrovascular accident—Doxorubicin—muscle cancer	7.05e-05	0.00142	CcSEcCtD
Dasatinib—CYP1A1—cardiac atrium—muscle cancer	7.03e-05	0.0013	CbGeAlD
Dasatinib—Decreased appetite—Vincristine—muscle cancer	7.03e-05	0.00141	CcSEcCtD
Dasatinib—Cough—Etoposide—muscle cancer	7e-05	0.00141	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Vincristine—muscle cancer	6.98e-05	0.0014	CcSEcCtD
Dasatinib—Fatigue—Vincristine—muscle cancer	6.97e-05	0.0014	CcSEcCtD
Dasatinib—Convulsion—Etoposide—muscle cancer	6.95e-05	0.0014	CcSEcCtD
Dasatinib—Hypertension—Etoposide—muscle cancer	6.93e-05	0.00139	CcSEcCtD
Dasatinib—Constipation—Vincristine—muscle cancer	6.91e-05	0.00139	CcSEcCtD
Dasatinib—Pain—Vincristine—muscle cancer	6.91e-05	0.00139	CcSEcCtD
Dasatinib—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	6.91e-05	0.00139	CcSEcCtD
Dasatinib—Asthma—Methotrexate—muscle cancer	6.9e-05	0.00139	CcSEcCtD
Dasatinib—Chest pain—Etoposide—muscle cancer	6.83e-05	0.00137	CcSEcCtD
Dasatinib—Affect lability—Doxorubicin—muscle cancer	6.8e-05	0.00137	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	6.79e-05	0.00136	CcSEcCtD
Dasatinib—Pancreatitis—Methotrexate—muscle cancer	6.76e-05	0.00136	CcSEcCtD
Dasatinib—Discomfort—Etoposide—muscle cancer	6.75e-05	0.00136	CcSEcCtD
Dasatinib—Face oedema—Doxorubicin—muscle cancer	6.67e-05	0.00134	CcSEcCtD
Dasatinib—Hypersensitivity—Dactinomycin—muscle cancer	6.67e-05	0.00134	CcSEcCtD
Dasatinib—Gastrointestinal pain—Vincristine—muscle cancer	6.61e-05	0.00133	CcSEcCtD
Dasatinib—Confusional state—Etoposide—muscle cancer	6.6e-05	0.00133	CcSEcCtD
Dasatinib—Pancytopenia—Methotrexate—muscle cancer	6.55e-05	0.00132	CcSEcCtD
Dasatinib—Infection—Etoposide—muscle cancer	6.51e-05	0.00131	CcSEcCtD
Dasatinib—Asthenia—Dactinomycin—muscle cancer	6.49e-05	0.0013	CcSEcCtD
Dasatinib—Blood creatinine increased—Doxorubicin—muscle cancer	6.48e-05	0.0013	CcSEcCtD
Dasatinib—Neutropenia—Methotrexate—muscle cancer	6.45e-05	0.0013	CcSEcCtD
Dasatinib—Thrombocytopenia—Etoposide—muscle cancer	6.41e-05	0.00129	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Methotrexate—muscle cancer	6.41e-05	0.00129	CcSEcCtD
Dasatinib—Tachycardia—Etoposide—muscle cancer	6.39e-05	0.00128	CcSEcCtD
Dasatinib—Abdominal pain—Vincristine—muscle cancer	6.39e-05	0.00128	CcSEcCtD
Dasatinib—Body temperature increased—Vincristine—muscle cancer	6.39e-05	0.00128	CcSEcCtD
Dasatinib—Skin disorder—Etoposide—muscle cancer	6.36e-05	0.00128	CcSEcCtD
Dasatinib—Dry skin—Doxorubicin—muscle cancer	6.34e-05	0.00127	CcSEcCtD
Dasatinib—Hyperhidrosis—Etoposide—muscle cancer	6.33e-05	0.00127	CcSEcCtD
Dasatinib—Photosensitivity reaction—Methotrexate—muscle cancer	6.3e-05	0.00126	CcSEcCtD
Dasatinib—Hypokalaemia—Doxorubicin—muscle cancer	6.29e-05	0.00126	CcSEcCtD
Dasatinib—ABCG2—bone marrow—muscle cancer	6.25e-05	0.00116	CbGeAlD
Dasatinib—Breast disorder—Doxorubicin—muscle cancer	6.25e-05	0.00125	CcSEcCtD
Dasatinib—Anorexia—Etoposide—muscle cancer	6.24e-05	0.00125	CcSEcCtD
Dasatinib—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	6.22e-05	0.00125	CcSEcCtD
Dasatinib—Diarrhoea—Dactinomycin—muscle cancer	6.19e-05	0.00124	CcSEcCtD
Dasatinib—Pneumonia—Methotrexate—muscle cancer	6.19e-05	0.00124	CcSEcCtD
Dasatinib—Infestation NOS—Methotrexate—muscle cancer	6.15e-05	0.00124	CcSEcCtD
Dasatinib—Infestation—Methotrexate—muscle cancer	6.15e-05	0.00124	CcSEcCtD
Dasatinib—Hypotension—Etoposide—muscle cancer	6.12e-05	0.00123	CcSEcCtD
Dasatinib—Gastritis—Doxorubicin—muscle cancer	6.12e-05	0.00123	CcSEcCtD
Dasatinib—Muscular weakness—Doxorubicin—muscle cancer	6.1e-05	0.00122	CcSEcCtD
Dasatinib—Alanine aminotransferase increased—Doxorubicin—muscle cancer	6.1e-05	0.00122	CcSEcCtD
Dasatinib—Renal failure—Methotrexate—muscle cancer	6.05e-05	0.00121	CcSEcCtD
Dasatinib—Abdominal distension—Doxorubicin—muscle cancer	6.01e-05	0.00121	CcSEcCtD
Dasatinib—Stomatitis—Methotrexate—muscle cancer	6e-05	0.0012	CcSEcCtD
Dasatinib—ABCG2—vagina—muscle cancer	5.99e-05	0.00111	CbGeAlD
Dasatinib—Conjunctivitis—Methotrexate—muscle cancer	5.98e-05	0.0012	CcSEcCtD
Dasatinib—Dysphagia—Doxorubicin—muscle cancer	5.97e-05	0.0012	CcSEcCtD
Dasatinib—Asthma—Doxorubicin—muscle cancer	5.97e-05	0.0012	CcSEcCtD
Dasatinib—Hypersensitivity—Vincristine—muscle cancer	5.96e-05	0.0012	CcSEcCtD
Dasatinib—Haematuria—Methotrexate—muscle cancer	5.87e-05	0.00118	CcSEcCtD
Dasatinib—Pancreatitis—Doxorubicin—muscle cancer	5.86e-05	0.00118	CcSEcCtD
Dasatinib—Dyspnoea—Etoposide—muscle cancer	5.84e-05	0.00117	CcSEcCtD
Dasatinib—Somnolence—Etoposide—muscle cancer	5.82e-05	0.00117	CcSEcCtD
Dasatinib—Angina pectoris—Doxorubicin—muscle cancer	5.82e-05	0.00117	CcSEcCtD
Dasatinib—Hepatobiliary disease—Methotrexate—muscle cancer	5.82e-05	0.00117	CcSEcCtD
Dasatinib—Epistaxis—Methotrexate—muscle cancer	5.8e-05	0.00117	CcSEcCtD
Dasatinib—Asthenia—Vincristine—muscle cancer	5.8e-05	0.00117	CcSEcCtD
Dasatinib—CYP3A4—renal system—muscle cancer	5.76e-05	0.00107	CbGeAlD
Dasatinib—Vomiting—Dactinomycin—muscle cancer	5.75e-05	0.00116	CcSEcCtD
Dasatinib—Rash—Dactinomycin—muscle cancer	5.71e-05	0.00115	CcSEcCtD
Dasatinib—Decreased appetite—Etoposide—muscle cancer	5.69e-05	0.00114	CcSEcCtD
Dasatinib—CYP1A1—vagina—muscle cancer	5.69e-05	0.00105	CbGeAlD
Dasatinib—Pancytopenia—Doxorubicin—muscle cancer	5.67e-05	0.00114	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Etoposide—muscle cancer	5.65e-05	0.00114	CcSEcCtD
Dasatinib—Fatigue—Etoposide—muscle cancer	5.65e-05	0.00113	CcSEcCtD
Dasatinib—Constipation—Etoposide—muscle cancer	5.6e-05	0.00112	CcSEcCtD
Dasatinib—Pain—Etoposide—muscle cancer	5.6e-05	0.00112	CcSEcCtD
Dasatinib—Neutropenia—Doxorubicin—muscle cancer	5.59e-05	0.00112	CcSEcCtD
Dasatinib—CYP3A5—vagina—muscle cancer	5.56e-05	0.00103	CbGeAlD
Dasatinib—Upper respiratory tract infection—Doxorubicin—muscle cancer	5.55e-05	0.00112	CcSEcCtD
Dasatinib—Haemoglobin—Methotrexate—muscle cancer	5.55e-05	0.00111	CcSEcCtD
Dasatinib—Diarrhoea—Vincristine—muscle cancer	5.53e-05	0.00111	CcSEcCtD
Dasatinib—Haemorrhage—Methotrexate—muscle cancer	5.52e-05	0.00111	CcSEcCtD
Dasatinib—Hepatitis—Methotrexate—muscle cancer	5.52e-05	0.00111	CcSEcCtD
Dasatinib—Pollakiuria—Doxorubicin—muscle cancer	5.52e-05	0.00111	CcSEcCtD
Dasatinib—Urinary tract disorder—Methotrexate—muscle cancer	5.45e-05	0.0011	CcSEcCtD
Dasatinib—Photosensitivity reaction—Doxorubicin—muscle cancer	5.45e-05	0.0011	CcSEcCtD
Dasatinib—Weight increased—Doxorubicin—muscle cancer	5.44e-05	0.00109	CcSEcCtD
Dasatinib—Urethral disorder—Methotrexate—muscle cancer	5.41e-05	0.00109	CcSEcCtD
Dasatinib—Weight decreased—Doxorubicin—muscle cancer	5.4e-05	0.00109	CcSEcCtD
Dasatinib—Feeling abnormal—Etoposide—muscle cancer	5.4e-05	0.00108	CcSEcCtD
Dasatinib—ABCB1—embryo—muscle cancer	5.39e-05	0.000999	CbGeAlD
Dasatinib—Nausea—Dactinomycin—muscle cancer	5.38e-05	0.00108	CcSEcCtD
Dasatinib—Pneumonia—Doxorubicin—muscle cancer	5.36e-05	0.00108	CcSEcCtD
Dasatinib—Gastrointestinal pain—Etoposide—muscle cancer	5.36e-05	0.00108	CcSEcCtD
Dasatinib—Dizziness—Vincristine—muscle cancer	5.35e-05	0.00107	CcSEcCtD
Dasatinib—ABCG2—testis—muscle cancer	5.35e-05	0.000991	CbGeAlD
Dasatinib—Infestation NOS—Doxorubicin—muscle cancer	5.33e-05	0.00107	CcSEcCtD
Dasatinib—Infestation—Doxorubicin—muscle cancer	5.33e-05	0.00107	CcSEcCtD
Dasatinib—Visual impairment—Methotrexate—muscle cancer	5.32e-05	0.00107	CcSEcCtD
Dasatinib—CYP1A1—head—muscle cancer	5.25e-05	0.000974	CbGeAlD
Dasatinib—Renal failure—Doxorubicin—muscle cancer	5.24e-05	0.00105	CcSEcCtD
Dasatinib—Erythema multiforme—Methotrexate—muscle cancer	5.22e-05	0.00105	CcSEcCtD
Dasatinib—Neuropathy peripheral—Doxorubicin—muscle cancer	5.22e-05	0.00105	CcSEcCtD
Dasatinib—Urticaria—Etoposide—muscle cancer	5.2e-05	0.00105	CcSEcCtD
Dasatinib—Stomatitis—Doxorubicin—muscle cancer	5.19e-05	0.00104	CcSEcCtD
Dasatinib—Abdominal pain—Etoposide—muscle cancer	5.18e-05	0.00104	CcSEcCtD
Dasatinib—Body temperature increased—Etoposide—muscle cancer	5.18e-05	0.00104	CcSEcCtD
Dasatinib—Conjunctivitis—Doxorubicin—muscle cancer	5.18e-05	0.00104	CcSEcCtD
Dasatinib—Eye disorder—Methotrexate—muscle cancer	5.16e-05	0.00104	CcSEcCtD
Dasatinib—Tinnitus—Methotrexate—muscle cancer	5.15e-05	0.00103	CcSEcCtD
Dasatinib—Vomiting—Vincristine—muscle cancer	5.14e-05	0.00103	CcSEcCtD
Dasatinib—Cardiac disorder—Methotrexate—muscle cancer	5.13e-05	0.00103	CcSEcCtD
Dasatinib—Rash—Vincristine—muscle cancer	5.1e-05	0.00102	CcSEcCtD
Dasatinib—Dermatitis—Vincristine—muscle cancer	5.09e-05	0.00102	CcSEcCtD
Dasatinib—Haematuria—Doxorubicin—muscle cancer	5.08e-05	0.00102	CcSEcCtD
Dasatinib—Headache—Vincristine—muscle cancer	5.07e-05	0.00102	CcSEcCtD
Dasatinib—Hepatobiliary disease—Doxorubicin—muscle cancer	5.04e-05	0.00101	CcSEcCtD
Dasatinib—Epistaxis—Doxorubicin—muscle cancer	5.02e-05	0.00101	CcSEcCtD
Dasatinib—Angiopathy—Methotrexate—muscle cancer	5.01e-05	0.00101	CcSEcCtD
Dasatinib—Immune system disorder—Methotrexate—muscle cancer	4.99e-05	0.001	CcSEcCtD
Dasatinib—Mediastinal disorder—Methotrexate—muscle cancer	4.98e-05	0.001	CcSEcCtD
Dasatinib—Chills—Methotrexate—muscle cancer	4.95e-05	0.000995	CcSEcCtD
Dasatinib—Alopecia—Methotrexate—muscle cancer	4.88e-05	0.00098	CcSEcCtD
Dasatinib—Mental disorder—Methotrexate—muscle cancer	4.84e-05	0.000972	CcSEcCtD
Dasatinib—Hypersensitivity—Etoposide—muscle cancer	4.83e-05	0.000969	CcSEcCtD
Dasatinib—Malnutrition—Methotrexate—muscle cancer	4.81e-05	0.000966	CcSEcCtD
Dasatinib—Erythema—Methotrexate—muscle cancer	4.81e-05	0.000966	CcSEcCtD
Dasatinib—Haemoglobin—Doxorubicin—muscle cancer	4.81e-05	0.000965	CcSEcCtD
Dasatinib—Nausea—Vincristine—muscle cancer	4.8e-05	0.000965	CcSEcCtD
Dasatinib—Hepatitis—Doxorubicin—muscle cancer	4.78e-05	0.00096	CcSEcCtD
Dasatinib—Haemorrhage—Doxorubicin—muscle cancer	4.78e-05	0.00096	CcSEcCtD
Dasatinib—Urinary tract disorder—Doxorubicin—muscle cancer	4.72e-05	0.000948	CcSEcCtD
Dasatinib—Oedema peripheral—Doxorubicin—muscle cancer	4.71e-05	0.000946	CcSEcCtD
Dasatinib—Dysgeusia—Methotrexate—muscle cancer	4.71e-05	0.000946	CcSEcCtD
Dasatinib—Asthenia—Etoposide—muscle cancer	4.7e-05	0.000944	CcSEcCtD
Dasatinib—Connective tissue disorder—Doxorubicin—muscle cancer	4.7e-05	0.000944	CcSEcCtD
Dasatinib—Urethral disorder—Doxorubicin—muscle cancer	4.69e-05	0.000941	CcSEcCtD
Dasatinib—Pruritus—Etoposide—muscle cancer	4.63e-05	0.000931	CcSEcCtD
Dasatinib—Visual impairment—Doxorubicin—muscle cancer	4.61e-05	0.000926	CcSEcCtD
Dasatinib—Vision blurred—Methotrexate—muscle cancer	4.53e-05	0.00091	CcSEcCtD
Dasatinib—Erythema multiforme—Doxorubicin—muscle cancer	4.52e-05	0.000908	CcSEcCtD
Dasatinib—Diarrhoea—Etoposide—muscle cancer	4.48e-05	0.0009	CcSEcCtD
Dasatinib—Eye disorder—Doxorubicin—muscle cancer	4.47e-05	0.000898	CcSEcCtD
Dasatinib—Ill-defined disorder—Methotrexate—muscle cancer	4.46e-05	0.000896	CcSEcCtD
Dasatinib—Tinnitus—Doxorubicin—muscle cancer	4.46e-05	0.000895	CcSEcCtD
Dasatinib—Anaemia—Methotrexate—muscle cancer	4.44e-05	0.000892	CcSEcCtD
Dasatinib—Cardiac disorder—Doxorubicin—muscle cancer	4.44e-05	0.000891	CcSEcCtD
Dasatinib—Flushing—Doxorubicin—muscle cancer	4.44e-05	0.000891	CcSEcCtD
Dasatinib—Angiopathy—Doxorubicin—muscle cancer	4.34e-05	0.000871	CcSEcCtD
Dasatinib—Malaise—Methotrexate—muscle cancer	4.34e-05	0.000871	CcSEcCtD
Dasatinib—Dizziness—Etoposide—muscle cancer	4.33e-05	0.00087	CcSEcCtD
Dasatinib—Immune system disorder—Doxorubicin—muscle cancer	4.32e-05	0.000867	CcSEcCtD
Dasatinib—Vertigo—Methotrexate—muscle cancer	4.32e-05	0.000867	CcSEcCtD
Dasatinib—Mediastinal disorder—Doxorubicin—muscle cancer	4.31e-05	0.000866	CcSEcCtD
Dasatinib—Chills—Doxorubicin—muscle cancer	4.29e-05	0.000862	CcSEcCtD
Dasatinib—Arrhythmia—Doxorubicin—muscle cancer	4.27e-05	0.000858	CcSEcCtD
Dasatinib—Alopecia—Doxorubicin—muscle cancer	4.23e-05	0.000849	CcSEcCtD
Dasatinib—Cough—Methotrexate—muscle cancer	4.19e-05	0.000843	CcSEcCtD
Dasatinib—Mental disorder—Doxorubicin—muscle cancer	4.19e-05	0.000841	CcSEcCtD
Dasatinib—Convulsion—Methotrexate—muscle cancer	4.17e-05	0.000837	CcSEcCtD
Dasatinib—Vomiting—Etoposide—muscle cancer	4.16e-05	0.000836	CcSEcCtD
Dasatinib—Erythema—Doxorubicin—muscle cancer	4.16e-05	0.000836	CcSEcCtD
Dasatinib—Malnutrition—Doxorubicin—muscle cancer	4.16e-05	0.000836	CcSEcCtD
Dasatinib—Rash—Etoposide—muscle cancer	4.13e-05	0.000829	CcSEcCtD
Dasatinib—Dermatitis—Etoposide—muscle cancer	4.13e-05	0.000829	CcSEcCtD
Dasatinib—Headache—Etoposide—muscle cancer	4.1e-05	0.000824	CcSEcCtD
Dasatinib—Arthralgia—Methotrexate—muscle cancer	4.09e-05	0.000822	CcSEcCtD
Dasatinib—Myalgia—Methotrexate—muscle cancer	4.09e-05	0.000822	CcSEcCtD
Dasatinib—Chest pain—Methotrexate—muscle cancer	4.09e-05	0.000822	CcSEcCtD
Dasatinib—ABCB1—renal system—muscle cancer	4.08e-05	0.000756	CbGeAlD
Dasatinib—Dysgeusia—Doxorubicin—muscle cancer	4.08e-05	0.000819	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	4.06e-05	0.000816	CcSEcCtD
Dasatinib—Discomfort—Methotrexate—muscle cancer	4.04e-05	0.000812	CcSEcCtD
Dasatinib—Muscle spasms—Doxorubicin—muscle cancer	4e-05	0.000804	CcSEcCtD
Dasatinib—Confusional state—Methotrexate—muscle cancer	3.96e-05	0.000795	CcSEcCtD
Dasatinib—Vision blurred—Doxorubicin—muscle cancer	3.92e-05	0.000788	CcSEcCtD
Dasatinib—Infection—Methotrexate—muscle cancer	3.9e-05	0.000783	CcSEcCtD
Dasatinib—Nausea—Etoposide—muscle cancer	3.89e-05	0.000781	CcSEcCtD
Dasatinib—Ill-defined disorder—Doxorubicin—muscle cancer	3.86e-05	0.000776	CcSEcCtD
Dasatinib—Nervous system disorder—Methotrexate—muscle cancer	3.85e-05	0.000773	CcSEcCtD
Dasatinib—Anaemia—Doxorubicin—muscle cancer	3.85e-05	0.000773	CcSEcCtD
Dasatinib—Thrombocytopenia—Methotrexate—muscle cancer	3.84e-05	0.000772	CcSEcCtD
Dasatinib—Skin disorder—Methotrexate—muscle cancer	3.81e-05	0.000765	CcSEcCtD
Dasatinib—Hyperhidrosis—Methotrexate—muscle cancer	3.79e-05	0.000762	CcSEcCtD
Dasatinib—Malaise—Doxorubicin—muscle cancer	3.75e-05	0.000754	CcSEcCtD
Dasatinib—Vertigo—Doxorubicin—muscle cancer	3.74e-05	0.000751	CcSEcCtD
Dasatinib—Anorexia—Methotrexate—muscle cancer	3.74e-05	0.000751	CcSEcCtD
Dasatinib—Syncope—Doxorubicin—muscle cancer	3.73e-05	0.00075	CcSEcCtD
Dasatinib—Palpitations—Doxorubicin—muscle cancer	3.68e-05	0.000739	CcSEcCtD
Dasatinib—Hypotension—Methotrexate—muscle cancer	3.67e-05	0.000736	CcSEcCtD
Dasatinib—Loss of consciousness—Doxorubicin—muscle cancer	3.66e-05	0.000735	CcSEcCtD
Dasatinib—Cough—Doxorubicin—muscle cancer	3.63e-05	0.00073	CcSEcCtD
Dasatinib—Convulsion—Doxorubicin—muscle cancer	3.61e-05	0.000724	CcSEcCtD
Dasatinib—Hypertension—Doxorubicin—muscle cancer	3.59e-05	0.000722	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Methotrexate—muscle cancer	3.57e-05	0.000718	CcSEcCtD
Dasatinib—Insomnia—Methotrexate—muscle cancer	3.55e-05	0.000713	CcSEcCtD
Dasatinib—Chest pain—Doxorubicin—muscle cancer	3.54e-05	0.000712	CcSEcCtD
Dasatinib—Myalgia—Doxorubicin—muscle cancer	3.54e-05	0.000712	CcSEcCtD
Dasatinib—Arthralgia—Doxorubicin—muscle cancer	3.54e-05	0.000712	CcSEcCtD
Dasatinib—Anxiety—Doxorubicin—muscle cancer	3.53e-05	0.000709	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	3.52e-05	0.000707	CcSEcCtD
Dasatinib—Discomfort—Doxorubicin—muscle cancer	3.5e-05	0.000703	CcSEcCtD
Dasatinib—Dyspnoea—Methotrexate—muscle cancer	3.5e-05	0.000703	CcSEcCtD
Dasatinib—Somnolence—Methotrexate—muscle cancer	3.49e-05	0.000701	CcSEcCtD
Dasatinib—Dyspepsia—Methotrexate—muscle cancer	3.45e-05	0.000694	CcSEcCtD
Dasatinib—Confusional state—Doxorubicin—muscle cancer	3.43e-05	0.000688	CcSEcCtD
Dasatinib—Decreased appetite—Methotrexate—muscle cancer	3.41e-05	0.000685	CcSEcCtD
Dasatinib—Oedema—Doxorubicin—muscle cancer	3.4e-05	0.000682	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Methotrexate—muscle cancer	3.39e-05	0.00068	CcSEcCtD
Dasatinib—Fatigue—Methotrexate—muscle cancer	3.38e-05	0.000679	CcSEcCtD
Dasatinib—Infection—Doxorubicin—muscle cancer	3.38e-05	0.000678	CcSEcCtD
Dasatinib—Pain—Methotrexate—muscle cancer	3.36e-05	0.000674	CcSEcCtD
Dasatinib—Shock—Doxorubicin—muscle cancer	3.34e-05	0.000671	CcSEcCtD
Dasatinib—Nervous system disorder—Doxorubicin—muscle cancer	3.33e-05	0.000669	CcSEcCtD
Dasatinib—Thrombocytopenia—Doxorubicin—muscle cancer	3.33e-05	0.000668	CcSEcCtD
Dasatinib—Tachycardia—Doxorubicin—muscle cancer	3.32e-05	0.000666	CcSEcCtD
Dasatinib—Skin disorder—Doxorubicin—muscle cancer	3.3e-05	0.000663	CcSEcCtD
Dasatinib—Hyperhidrosis—Doxorubicin—muscle cancer	3.28e-05	0.00066	CcSEcCtD
Dasatinib—Anorexia—Doxorubicin—muscle cancer	3.24e-05	0.00065	CcSEcCtD
Dasatinib—Feeling abnormal—Methotrexate—muscle cancer	3.23e-05	0.000649	CcSEcCtD
Dasatinib—Gastrointestinal pain—Methotrexate—muscle cancer	3.21e-05	0.000644	CcSEcCtD
Dasatinib—Hypotension—Doxorubicin—muscle cancer	3.17e-05	0.000638	CcSEcCtD
Dasatinib—Urticaria—Methotrexate—muscle cancer	3.12e-05	0.000626	CcSEcCtD
Dasatinib—Abdominal pain—Methotrexate—muscle cancer	3.1e-05	0.000623	CcSEcCtD
Dasatinib—Body temperature increased—Methotrexate—muscle cancer	3.1e-05	0.000623	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Doxorubicin—muscle cancer	3.1e-05	0.000622	CcSEcCtD
Dasatinib—ABCB1—bone marrow—muscle cancer	3.08e-05	0.000572	CbGeAlD
Dasatinib—Insomnia—Doxorubicin—muscle cancer	3.07e-05	0.000617	CcSEcCtD
Dasatinib—Dyspnoea—Doxorubicin—muscle cancer	3.03e-05	0.000608	CcSEcCtD
Dasatinib—Somnolence—Doxorubicin—muscle cancer	3.02e-05	0.000607	CcSEcCtD
Dasatinib—Dyspepsia—Doxorubicin—muscle cancer	2.99e-05	0.000601	CcSEcCtD
Dasatinib—ABCB1—vagina—muscle cancer	2.95e-05	0.000548	CbGeAlD
Dasatinib—Decreased appetite—Doxorubicin—muscle cancer	2.95e-05	0.000593	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Doxorubicin—muscle cancer	2.93e-05	0.000589	CcSEcCtD
Dasatinib—Fatigue—Doxorubicin—muscle cancer	2.93e-05	0.000588	CcSEcCtD
Dasatinib—Pain—Doxorubicin—muscle cancer	2.91e-05	0.000583	CcSEcCtD
Dasatinib—Constipation—Doxorubicin—muscle cancer	2.91e-05	0.000583	CcSEcCtD
Dasatinib—Hypersensitivity—Methotrexate—muscle cancer	2.89e-05	0.000581	CcSEcCtD
Dasatinib—Asthenia—Methotrexate—muscle cancer	2.81e-05	0.000565	CcSEcCtD
Dasatinib—Feeling abnormal—Doxorubicin—muscle cancer	2.8e-05	0.000562	CcSEcCtD
Dasatinib—Gastrointestinal pain—Doxorubicin—muscle cancer	2.78e-05	0.000558	CcSEcCtD
Dasatinib—Pruritus—Methotrexate—muscle cancer	2.78e-05	0.000558	CcSEcCtD
Dasatinib—ABCB1—head—muscle cancer	2.73e-05	0.000506	CbGeAlD
Dasatinib—Urticaria—Doxorubicin—muscle cancer	2.7e-05	0.000542	CcSEcCtD
Dasatinib—Abdominal pain—Doxorubicin—muscle cancer	2.69e-05	0.000539	CcSEcCtD
Dasatinib—Body temperature increased—Doxorubicin—muscle cancer	2.69e-05	0.000539	CcSEcCtD
Dasatinib—Diarrhoea—Methotrexate—muscle cancer	2.68e-05	0.000539	CcSEcCtD
Dasatinib—ABCB1—testis—muscle cancer	2.64e-05	0.000489	CbGeAlD
Dasatinib—Dizziness—Methotrexate—muscle cancer	2.59e-05	0.000521	CcSEcCtD
Dasatinib—Hypersensitivity—Doxorubicin—muscle cancer	2.5e-05	0.000503	CcSEcCtD
Dasatinib—Vomiting—Methotrexate—muscle cancer	2.49e-05	0.000501	CcSEcCtD
Dasatinib—Rash—Methotrexate—muscle cancer	2.47e-05	0.000497	CcSEcCtD
Dasatinib—Dermatitis—Methotrexate—muscle cancer	2.47e-05	0.000496	CcSEcCtD
Dasatinib—Headache—Methotrexate—muscle cancer	2.46e-05	0.000494	CcSEcCtD
Dasatinib—Asthenia—Doxorubicin—muscle cancer	2.44e-05	0.00049	CcSEcCtD
Dasatinib—Pruritus—Doxorubicin—muscle cancer	2.4e-05	0.000483	CcSEcCtD
Dasatinib—Nausea—Methotrexate—muscle cancer	2.33e-05	0.000468	CcSEcCtD
Dasatinib—Diarrhoea—Doxorubicin—muscle cancer	2.32e-05	0.000467	CcSEcCtD
Dasatinib—Dizziness—Doxorubicin—muscle cancer	2.25e-05	0.000451	CcSEcCtD
Dasatinib—Vomiting—Doxorubicin—muscle cancer	2.16e-05	0.000434	CcSEcCtD
Dasatinib—Rash—Doxorubicin—muscle cancer	2.14e-05	0.00043	CcSEcCtD
Dasatinib—Dermatitis—Doxorubicin—muscle cancer	2.14e-05	0.00043	CcSEcCtD
Dasatinib—Headache—Doxorubicin—muscle cancer	2.13e-05	0.000427	CcSEcCtD
Dasatinib—Nausea—Doxorubicin—muscle cancer	2.02e-05	0.000405	CcSEcCtD
Dasatinib—LCK—Immune System—FOXO4—muscle cancer	5.81e-06	8.14e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—FOXO1—muscle cancer	5.79e-06	8.11e-05	CbGpPWpGaD
Dasatinib—HCK—Immune System—MDM2—muscle cancer	5.78e-06	8.1e-05	CbGpPWpGaD
Dasatinib—FGR—Hemostasis—TP53—muscle cancer	5.71e-06	8e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	5.67e-06	7.95e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—KIT—muscle cancer	5.62e-06	7.88e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—IGF2—muscle cancer	5.62e-06	7.87e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—KIT—muscle cancer	5.61e-06	7.86e-05	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	5.6e-06	7.86e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—FH—muscle cancer	5.6e-06	7.85e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Innate Immune System—MDM2—muscle cancer	5.51e-06	7.72e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—FOXO4—muscle cancer	5.49e-06	7.69e-05	CbGpPWpGaD
Dasatinib—MAPK14—Cellular responses to stress—TP53—muscle cancer	5.48e-06	7.68e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—FOXO1—muscle cancer	5.48e-06	7.68e-05	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—MDM2—muscle cancer	5.44e-06	7.63e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PTCH1—muscle cancer	5.44e-06	7.63e-05	CbGpPWpGaD
Dasatinib—SRC—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	5.44e-06	7.62e-05	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	5.4e-06	7.57e-05	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—MDM2—muscle cancer	5.39e-06	7.56e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—KIT—muscle cancer	5.39e-06	7.55e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CNR1—muscle cancer	5.38e-06	7.55e-05	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—MDM2—muscle cancer	5.37e-06	7.52e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—FOXO1—muscle cancer	5.36e-06	7.52e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—FOXO4—muscle cancer	5.36e-06	7.51e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—KIT—muscle cancer	5.35e-06	7.49e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—FOXO1—muscle cancer	5.34e-06	7.49e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—ENO2—muscle cancer	5.34e-06	7.48e-05	CbGpPWpGaD
Dasatinib—HCK—Disease—MDM2—muscle cancer	5.33e-06	7.48e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PTCH1—muscle cancer	5.33e-06	7.47e-05	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—MDM2—muscle cancer	5.31e-06	7.44e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—HMGA1—muscle cancer	5.29e-06	7.42e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Adaptive Immune System—MDM2—muscle cancer	5.29e-06	7.41e-05	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—VEGFA—muscle cancer	5.24e-06	7.35e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PTCH1—muscle cancer	5.24e-06	7.35e-05	CbGpPWpGaD
Dasatinib—BLK—Immune System—MDM2—muscle cancer	5.23e-06	7.34e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—FOXO1—muscle cancer	5.23e-06	7.33e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—MDM2—muscle cancer	5.22e-06	7.31e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—FOXO1—muscle cancer	5.21e-06	7.3e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—FOXO4—muscle cancer	5.19e-06	7.28e-05	CbGpPWpGaD
Dasatinib—LYN—Adaptive Immune System—MDM2—muscle cancer	5.18e-06	7.26e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—FOXO1—muscle cancer	5.17e-06	7.24e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—FOXO1—muscle cancer	5.15e-06	7.22e-05	CbGpPWpGaD
Dasatinib—HCK—Disease—PTGS2—muscle cancer	5.14e-06	7.21e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—FOXO4—muscle cancer	5.14e-06	7.21e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—MDM2—muscle cancer	5.11e-06	7.16e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CNR1—muscle cancer	5.1e-06	7.14e-05	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—MDM2—muscle cancer	5.1e-06	7.14e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PTCH1—muscle cancer	5.05e-06	7.08e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—MDM2—muscle cancer	5.04e-06	7.07e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PTCH1—muscle cancer	4.98e-06	6.99e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—KIT—muscle cancer	4.97e-06	6.96e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—FOXO1—muscle cancer	4.96e-06	6.95e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—FOXO1—muscle cancer	4.93e-06	6.92e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IGF2—muscle cancer	4.93e-06	6.91e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—FOXO1—muscle cancer	4.9e-06	6.86e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—MDM2—muscle cancer	4.87e-06	6.82e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—MDM2—muscle cancer	4.8e-06	6.72e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—KIT—muscle cancer	4.77e-06	6.69e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—FOXO1—muscle cancer	4.76e-06	6.67e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—FOXO4—muscle cancer	4.75e-06	6.65e-05	CbGpPWpGaD
Dasatinib—SRC—Axon guidance—VEGFA—muscle cancer	4.71e-06	6.61e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—MDM2—muscle cancer	4.71e-06	6.61e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—FOXO4—muscle cancer	4.68e-06	6.56e-05	CbGpPWpGaD
Dasatinib—LYN—Developmental Biology—VEGFA—muscle cancer	4.63e-06	6.5e-05	CbGpPWpGaD
Dasatinib—ABL1—Developmental Biology—VEGFA—muscle cancer	4.61e-06	6.47e-05	CbGpPWpGaD
Dasatinib—YES1—Hemostasis—TP53—muscle cancer	4.61e-06	6.46e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CNR1—muscle cancer	4.59e-06	6.44e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	4.59e-06	6.43e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—FOXO4—muscle cancer	4.58e-06	6.42e-05	CbGpPWpGaD
Dasatinib—FYN—Developmental Biology—VEGFA—muscle cancer	4.56e-06	6.4e-05	CbGpPWpGaD
Dasatinib—FMO3—Metabolism—PTGS2—muscle cancer	4.55e-06	6.38e-05	CbGpPWpGaD
Dasatinib—LYN—Hemostasis—VEGFA—muscle cancer	4.55e-06	6.37e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—FOXO1—muscle cancer	4.54e-06	6.36e-05	CbGpPWpGaD
Dasatinib—ABL1—Hemostasis—VEGFA—muscle cancer	4.53e-06	6.34e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—FOXO1—muscle cancer	4.52e-06	6.34e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—KIT—muscle cancer	4.52e-06	6.34e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—FOXO4—muscle cancer	4.51e-06	6.32e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CNR1—muscle cancer	4.5e-06	6.3e-05	CbGpPWpGaD
Dasatinib—FYN—Hemostasis—VEGFA—muscle cancer	4.48e-06	6.27e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—FH—muscle cancer	4.47e-06	6.27e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—KIT—muscle cancer	4.47e-06	6.26e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—MDM2—muscle cancer	4.43e-06	6.21e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CNR1—muscle cancer	4.43e-06	6.2e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—MDM2—muscle cancer	4.42e-06	6.19e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IGF2—muscle cancer	4.4e-06	6.17e-05	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—VEGFA—muscle cancer	4.39e-06	6.16e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PTCH1—muscle cancer	4.37e-06	6.12e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—FOXO4—muscle cancer	4.34e-06	6.09e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—VEGFA—muscle cancer	4.34e-06	6.08e-05	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—VEGFA—muscle cancer	4.31e-06	6.04e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—FOXO1—muscle cancer	4.29e-06	6.01e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—FOXO4—muscle cancer	4.29e-06	6.01e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—PTGS2—muscle cancer	4.27e-06	5.98e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CNR1—muscle cancer	4.26e-06	5.97e-05	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	4.26e-06	5.97e-05	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—VEGFA—muscle cancer	4.26e-06	5.96e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—MDM2—muscle cancer	4.24e-06	5.95e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—MDM2—muscle cancer	4.21e-06	5.9e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CNR1—muscle cancer	4.21e-06	5.9e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—MED12—muscle cancer	4.19e-06	5.88e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—KIT—muscle cancer	4.17e-06	5.85e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IGF2—muscle cancer	4.17e-06	5.84e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—KIT—muscle cancer	4.09e-06	5.73e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—KIT—muscle cancer	4.07e-06	5.71e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—FOXO1—muscle cancer	4.05e-06	5.68e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—KIT—muscle cancer	3.99e-06	5.59e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—KIT—muscle cancer	3.97e-06	5.56e-05	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—TP53—muscle cancer	3.96e-06	5.55e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—MED12—muscle cancer	3.96e-06	5.55e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—FOXO1—muscle cancer	3.96e-06	5.55e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—KIT—muscle cancer	3.94e-06	5.52e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—KIT—muscle cancer	3.92e-06	5.5e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—MDM2—muscle cancer	3.91e-06	5.48e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PTCH1—muscle cancer	3.86e-06	5.42e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—FOXO1—muscle cancer	3.84e-06	5.38e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—ENO2—muscle cancer	3.82e-06	5.36e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—FOXO1—muscle cancer	3.8e-06	5.32e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—KIT—muscle cancer	3.78e-06	5.3e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—MDM2—muscle cancer	3.76e-06	5.27e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—KIT—muscle cancer	3.76e-06	5.27e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—MDM2—muscle cancer	3.76e-06	5.26e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—FOXO4—muscle cancer	3.75e-06	5.26e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IGF2—muscle cancer	3.75e-06	5.26e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—KIT—muscle cancer	3.73e-06	5.23e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—VEGFA—muscle cancer	3.73e-06	5.22e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—VEGFA—muscle cancer	3.69e-06	5.18e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CNR1—muscle cancer	3.69e-06	5.17e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IGF2—muscle cancer	3.68e-06	5.15e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—KIT—muscle cancer	3.62e-06	5.08e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IGF2—muscle cancer	3.62e-06	5.07e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—ENO2—muscle cancer	3.61e-06	5.06e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—VEGFA—muscle cancer	3.58e-06	5.02e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—MDM2—muscle cancer	3.56e-06	4.99e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—MDM2—muscle cancer	3.52e-06	4.93e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—FOXO1—muscle cancer	3.51e-06	4.91e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IGF2—muscle cancer	3.48e-06	4.88e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—MDM2—muscle cancer	3.47e-06	4.87e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—KIT—muscle cancer	3.46e-06	4.85e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—FOXO1—muscle cancer	3.46e-06	4.84e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—FH—muscle cancer	3.45e-06	4.84e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—KIT—muscle cancer	3.44e-06	4.83e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IGF2—muscle cancer	3.44e-06	4.82e-05	CbGpPWpGaD
Dasatinib—LYN—Hemostasis—TP53—muscle cancer	3.44e-06	4.82e-05	CbGpPWpGaD
Dasatinib—ABL1—Hemostasis—TP53—muscle cancer	3.42e-06	4.79e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—FOXO1—muscle cancer	3.38e-06	4.74e-05	CbGpPWpGaD
Dasatinib—FYN—Hemostasis—TP53—muscle cancer	3.38e-06	4.74e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—VEGFA—muscle cancer	3.36e-06	4.71e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—PTGS2—muscle cancer	3.35e-06	4.69e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—FOXO1—muscle cancer	3.33e-06	4.67e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—FOXO4—muscle cancer	3.32e-06	4.66e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—VEGFA—muscle cancer	3.3e-06	4.62e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—MDM2—muscle cancer	3.29e-06	4.61e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—KIT—muscle cancer	3.27e-06	4.58e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CNR1—muscle cancer	3.26e-06	4.57e-05	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—TP53—muscle cancer	3.26e-06	4.57e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—MDM2—muscle cancer	3.22e-06	4.51e-05	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	3.22e-06	4.51e-05	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—TP53—muscle cancer	3.22e-06	4.51e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—MDM2—muscle cancer	3.21e-06	4.49e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—FOXO1—muscle cancer	3.21e-06	4.49e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—PTGS2—muscle cancer	3.17e-06	4.44e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—FOXO1—muscle cancer	3.17e-06	4.44e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—MED12—muscle cancer	3.16e-06	4.44e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—MDM2—muscle cancer	3.14e-06	4.4e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—MDM2—muscle cancer	3.13e-06	4.38e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—MDM2—muscle cancer	3.1e-06	4.35e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—MDM2—muscle cancer	3.09e-06	4.33e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—KIT—muscle cancer	3.02e-06	4.23e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IGF2—muscle cancer	3.01e-06	4.22e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—MDM2—muscle cancer	2.98e-06	4.17e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—MDM2—muscle cancer	2.96e-06	4.15e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—MDM2—muscle cancer	2.94e-06	4.12e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KIT—muscle cancer	2.92e-06	4.1e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—KIT—muscle cancer	2.89e-06	4.05e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ENO2—muscle cancer	2.88e-06	4.04e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—PTGS2—muscle cancer	2.85e-06	4e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—MDM2—muscle cancer	2.85e-06	4e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.82e-06	3.96e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—TP53—muscle cancer	2.82e-06	3.95e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—TP53—muscle cancer	2.79e-06	3.91e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—FOXO1—muscle cancer	2.77e-06	3.89e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—PTGS2—muscle cancer	2.75e-06	3.86e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—MDM2—muscle cancer	2.72e-06	3.82e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—MDM2—muscle cancer	2.71e-06	3.8e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—TP53—muscle cancer	2.7e-06	3.79e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—VEGFA—muscle cancer	2.67e-06	3.74e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—KIT—muscle cancer	2.67e-06	3.74e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IGF2—muscle cancer	2.67e-06	3.74e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KIT—muscle cancer	2.63e-06	3.69e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—PTGS2—muscle cancer	2.62e-06	3.67e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KIT—muscle cancer	2.58e-06	3.61e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—MDM2—muscle cancer	2.57e-06	3.61e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KIT—muscle cancer	2.54e-06	3.56e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—MED12—muscle cancer	2.53e-06	3.54e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—TP53—muscle cancer	2.49e-06	3.49e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—FOXO1—muscle cancer	2.45e-06	3.44e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KIT—muscle cancer	2.44e-06	3.42e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—VEGFA—muscle cancer	2.44e-06	3.42e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MDM2—muscle cancer	2.43e-06	3.41e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KIT—muscle cancer	2.41e-06	3.38e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—MDM2—muscle cancer	2.38e-06	3.33e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—VEGFA—muscle cancer	2.36e-06	3.3e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ENO2—muscle cancer	2.3e-06	3.23e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MDM2—muscle cancer	2.3e-06	3.23e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—PTGS2—muscle cancer	2.29e-06	3.21e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—MDM2—muscle cancer	2.28e-06	3.19e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KIT—muscle cancer	2.11e-06	2.96e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—MDM2—muscle cancer	2.1e-06	2.95e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MDM2—muscle cancer	2.07e-06	2.91e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—VEGFA—muscle cancer	2.07e-06	2.9e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PTGS2—muscle cancer	2.04e-06	2.86e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MDM2—muscle cancer	2.03e-06	2.85e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—PTGS2—muscle cancer	2.03e-06	2.84e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TP53—muscle cancer	2.02e-06	2.83e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MDM2—muscle cancer	2e-06	2.8e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—MED12—muscle cancer	1.95e-06	2.73e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MDM2—muscle cancer	1.92e-06	2.7e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MDM2—muscle cancer	1.9e-06	2.66e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KIT—muscle cancer	1.87e-06	2.62e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PTGS2—muscle cancer	1.86e-06	2.6e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—VEGFA—muscle cancer	1.85e-06	2.59e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—muscle cancer	1.85e-06	2.59e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.8e-06	2.52e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—muscle cancer	1.78e-06	2.49e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ENO2—muscle cancer	1.78e-06	2.49e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—VEGFA—muscle cancer	1.75e-06	2.45e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MDM2—muscle cancer	1.66e-06	2.33e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—VEGFA—muscle cancer	1.57e-06	2.21e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—muscle cancer	1.56e-06	2.19e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—VEGFA—muscle cancer	1.54e-06	2.16e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—VEGFA—muscle cancer	1.52e-06	2.13e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MDM2—muscle cancer	1.47e-06	2.06e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—VEGFA—muscle cancer	1.46e-06	2.05e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—VEGFA—muscle cancer	1.44e-06	2.02e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—muscle cancer	1.39e-06	1.96e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTGS2—muscle cancer	1.33e-06	1.87e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—muscle cancer	1.32e-06	1.85e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—VEGFA—muscle cancer	1.26e-06	1.77e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTGS2—muscle cancer	1.26e-06	1.76e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—muscle cancer	1.19e-06	1.67e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—muscle cancer	1.16e-06	1.63e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—muscle cancer	1.15e-06	1.61e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—VEGFA—muscle cancer	1.12e-06	1.57e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—muscle cancer	1.1e-06	1.55e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—muscle cancer	1.09e-06	1.53e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTGS2—muscle cancer	1e-06	1.41e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—muscle cancer	9.55e-07	1.34e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—muscle cancer	8.45e-07	1.18e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTGS2—muscle cancer	8.02e-07	1.12e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTGS2—muscle cancer	6.19e-07	8.68e-06	CbGpPWpGaD
